Coherus BioSciences (CHRS) reported Q1 2026 earnings with an EPS of -$0.25, meeting expectations. However, revenue missed forecasts at $12.31M vs. $14.43M expected, a 14.69% shortfall. This led to a 2.29% after-hours stock decline, though premarket trading saw a 1.78% recovery.
LOQTORZI showed strong 61% year-over-year growth but quarterly sales fell 4.8% due to severe winter weather. The company remains unprofitable with a negative EBITDA of $163M.
Management projects reaching $15M quarterly revenue in 2026 and $30-35M in 2027. Cost management and pipeline investments support these goals.
Winter storms impacted Q1, but new patient starts reached an all-time high. The company focuses on expanding LOQTORZI adoption and reducing chemo-only use.
